Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $202.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price boosted by HC Wainwright from $200.00 to $202.00 in a research report report published on Wednesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($1.61) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at $0.14 EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at $2.64 EPS, FY2029 earnings at $6.85 EPS and FY2030 earnings at $10.76 EPS.

MIRM has been the topic of several other reports. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Stifel Nicolaus increased their price objective on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Citigroup boosted their price target on shares of Mirum Pharmaceuticals from $160.00 to $184.00 and gave the company a “buy” rating in a report on Monday, October 12th. Royal Bank Of Canada upped their price target on shares of Mirum Pharmaceuticals from $135.00 to $155.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Finally, TD Cowen upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $154.94.

Mirum Pharmaceuticals Price Performance

MIRM opened at $93.72 on Wednesday. Mirum Pharmaceuticals has a 1 year low of $63.23 and a 1 year high of $130.00. The company has a market capitalization of $6.09 billion, a price-to-earnings ratio of -6.06 and a beta of 0.75. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm’s fifty day moving average price is $89.29 and its two-hundred day moving average price is $98.46.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). The firm had revenue of $185.72 million for the quarter, compared to analysts’ expectations of $178.07 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s quarterly revenue was up 39.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.05 earnings per share. As a group, analysts anticipate that Mirum Pharmaceuticals will post -1.47 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 6,001 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $90.00, for a total value of $1,800,000.00. Following the transaction, the chief executive officer directly owned 206,637 shares of the company’s stock, valued at approximately $18,597,330. The trade was a 8.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 116,659 shares of company stock valued at $11,404,100. 8.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $27,000. Summit Securities Group LLC purchased a new position in Mirum Pharmaceuticals during the first quarter valued at $42,000. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at about $44,000. State of Wyoming purchased a new position in Mirum Pharmaceuticals during the 2nd quarter valued at about $52,000. Finally, Fifth Third Bancorp purchased a new position in shares of Mirum Pharmaceuticals in the first quarter worth about $56,000.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.